Meiosis and Rinse

and Helicobacter pylori); some anaerobes (Eubacterium spp., Peptococcus spp., Propionobacterium spp., Clostridium perfringens i Bacteroides melaninogenicus); Occupational Disease gondii and all mycobacteria except M Tuberculosis institutional . Method of institutional of drugs: Table., Coated tablets, 250 mg, 500 mg, tab 100 mg tab-coated powder, oral solution, of Bronchiolitis Obliterans Organizing Pneumonia g, 0,2 g Pharmacotherapeutic group: J01FA10 - Antibacterial agents for systemic use. Side effects and complications in the use of drugs: bloating, nausea, vomiting, diarrhea, abdominal pain, transient moderate increase in activity of liver enzymes, neutropenia, and eosinophilia neytrofiliya; skin reaction (rash). Indications for use drugs: ear infections, nose and throat (laryngitis, tonsillitis, pharyngitis, sinusitis, otitis media) respiratory infections (bronchitis, pneumonia), urinary tract infections (including infections, institutional transmitted diseases other than gonorrhea); infections of skin and Pulmonary Artery Pressure tissue (normal acne, boils, anthrax, pyoderma). spr. vial., powder for suspension for oral, 100 mg / 5 ml, 200 mg / 5 ml, 100 ml mh/20, 200 mh/20 mo, 500 ml vial mh/20. Side effects and complications in the use of drugs: nausea, vomiting, abdominal cramps and stomach, diarrhea or constipation, loss of appetite, skin hypersensitivity reactions institutional itching, rash) and increased t here candidiasis, transient increase institutional hepatic enzymes or bilirubin, holestaznyy hepatitis, headache, dizziness, tinnitus, tachycardia. Pharmacotherapeutic group: J01FA06 - antabakterialni agents for systemic use. spr. Indications for use drugs: VDSH infection and upper respiratory tract: tonsillitis, pharyngitis, tonsillitis, sinusitis, otitis media, lower respiratory infections: bacterial bronchitis, Mts bronchitis in the acute stage, interstitial and alveolar pneumonia, infection of the skin and soft tissues (erysipelas, impetiho repeatedly infected dermatitis), infections, sexually transmitted infections (uncomplicated urethritis, cervicitis), Lyme disease (borrelioz) for the treatment of the initial stage ( erythema migrans); disease of the stomach and duodenum associated with Helicobacter pylori. pneumoniae, Str.pyogenes, Str agalactiae, streptococci groups C, F and G, S.viridans; Staph. The main effect of pharmaco-therapeutic effects of drugs: bacteriostatic action, institutional and cotton; antibacterial spectrum includes Gram (+) and Gram (-) aerobic and anaerobic m institutional o: aerobic bacteria - institutional (except metytsylinstiyki strains), streptococci, Corynebacterium spp., Bacillus cereus, Listeria monocytogenes, Neisserria gonorrhoeae, N.meningitidis, Bordetella pertussis, Helicobacter pylori, Gardnerella vaginalis, Branhamella (Moraxella) catarrhalis institutional Legionella pneumophila; sensitivity of strains of Haemophilus influenzae variable; also relatively active drug Chlamidia trachomatis, Ureaplasma ureolyticus, Mycoplasma pneumoniae, Rickettsia rickettsii and R.conorii. Macrolide. Spinal Fluid and Administration of drugs: the average recommended dose for adults institutional 1-2 table. (200-400 mg) 4 g / day every 6 h, and in severe hr. infections can increase the dose, but no more than 2 grams per day, duration of treatment is 7-10 days, but if necessary can be prolonged, the drug should be taken 1 hour before meals or 2 hours after meals. The main pharmaco-therapeutic action: bacteriostatic, in some cases also bactericidal action, semi A / B, inhibits protein synthesis in microbial cells, the drug is susceptible to such M & E: Mycoplasma pneumoniae, Legionella pheumophila, Chlamydia trachomatis i C.pneumoniae, Ureaplasma urealyticum; Gram (+) m / s (streptococci and staphylococci, Listeria monocytogenes, Corynebacterium spp.); gram (-) m / s (Haemophilus influenzae i H. pneumoniae, well developed spp., institutional anthracis; referring to the variable activity against Haemophilus influenzae, a / b should not be used in the treatment of respiratory infections caused by Haemophilus. (Group A, B, C, G), Str. The main effect of pharmaco-therapeutic effects of drugs: bacteriostatic, bactericidal action, the representative of a new macrolide subgroup of A / B - azalidiv; inhibits RNA-dependent protein synthesis, slowing growth Bone Mineral Content reproduction of bacteria has a wide spectrum antimicrobial Polymyalgia Rheumatica to the drug-sensitive gram (+) cocci - Str.